<div id="readability-page-1">05:30 PM EST, 01/20/2026 (MT Newswires) -- BioAge Labs ( BIOA ) reported late Tuesday that it plans to launch a public offering of up to $75 million of common shares.Underwriters will be given a 30-day option to buy an additional $11.3 million of shares of its common stock, the company said.The biopharma company said it plans to use the proceeds from offering, along with its existing cash, to finance the advancement of its product candidates, including lead candidate BGE-102, for debt reduction and general corporate purposes, among others.Shares of the company fell more than 5% in recent after-hours activity. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

BioAge Labs 計劃公開發行最多 7500 萬美元的普通股，承銷商有 30 天的選擇權可增發 1130 萬美元。這些資金將用於推進產品候選者的開發，包括 BGE-102、減少債務以及一般企業用途。在公告發布後，股價在盤後交易中下跌超過 5%

BioAge Labs Proposes Public Offering Worth $75 Million

fidelity

基因改革 ETF - ARK

紐交所高增長板生物技術指數 ETF - First Trust

醫療業 ETF - SPDR

醫療業 ETF - Vanguard

美國制藥 ETF - iShares

生物科技 ETF - VanEck Vectors

標普全球醫療股指數 ETF - iShares

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

動態生物技術與基因組 ETF - Invesco

BioAge Labs

BioAge Labs 提議進行總額為 7500 萬美元的公開發行